How Phreesia, Inc. stacks up

PHR · against 552 other Healthcare companies listed in US-listed

Overall

54/ 100

Above the middle of the pack.

Ranked #150 of 553 · scores higher than 71% of peers

Bars: peers in each 10-point band of the overall score

96 peers with an overall score of 50–59, including PHR · Click a bar to see the companies

The four scores behind it

Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)

Valuation#163 of 589Score 53 / 100 · beats 71%Growth#176 of 455Score 75 / 100 · beats 60%Profitability#202 of 558Score 44 / 100 · beats 63%Risk#301 of 597Moderate relative risk · safety 43 · beats 50%

Ranking by overall score

Top 5 and the companies ranked around PHR

Rank	Company	Market cap	Overall	Valuation	Growth	Profitability	Risk
1	Arbutus Biopharma CorporationABUS · US-listed	595M USD	97	96	98	99	0 / 2
1	Q32 Bio Inc.QTTB · US-listed	261M USD	97	93	—	98	0 / 2
3	Lakefront Biotherapeutics NVLKFT · US-listed	2.1B USD	96	96	99	93	0 / 2
4	Innoviva, Inc.INVA · US-listed	1.5B USD	93	94	91	93	0 / 2
5	Zevra Therapeutics, Inc.ZVRA · US-listed	609M USD	91	95	99	99	0 / 2

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score